Drug Trial Radar · NCT02978326
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
Last checked: Nov 20, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
276
Actual
Start
Jan 4, 2017
Primary completion
Nov 15, 2018
Study completion Dec 11, 2018
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Nov 30, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score at Day 15 and to evaluate the safety and tolerability of SAGE-217 compared to placebo as assessed by the incidence of adverse events, vital sign measurements, clinical laboratory evaluations, electrocardiogram (ECG) parameters, and the Columbia Suicide Severity Rating Scale (C-SSRS).
Conditions
- Postpartum Depression
Interventions
SAGE-217 15/20 mg Oral SolutionDrug
SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).
PlaceboDrug
SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
SAGE 217 30 mg CapsulesDrug
SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Change From Baseline in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15Time frame: Parts A and B: Baseline, Day 15
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Sage Investigational Site
Little Rock, Arkansas
Sage Investigational Site
Beverly Hills, California
Sage Investigational Site
Oceanside, California
Sage Investigational Site
Wildomar, California
Sage Investigational Site
Washington D.C., District of Columbia
Sage Investigational Site
Aventura, Florida
Sage Investigational Site
Miami, Florida
Sage Investigational Site
Orlando, Florida
Sage Investigational Site
Pensacola, Florida
Sage Investigational SIte
Pinellas Park, Florida
Sage Investigational Site
Atlanta, Georgia
Sage Investigational Site
Decatur, Georgia
Sage Investigational Site
Hoffman Estates, Illinois
Sage Investigational Site
Owensboro, Kentucky
Sage Investigational Site
Lake Charles, Louisiana
Sage Investigational Site
New Orleans, Louisiana
Sage Investigational Site
Saint Charles, Missouri
Sage Investigational Site
Las Vegas, Nevada
Sage Investigational Site
Manhasset, New York
Sage Investigational Site
New York, New York
Sage Investigational Site
Chapel Hill, North Carolina
Sage Investigational Site
Raleigh, North Carolina
Sage Investigational Site
Providence, Rhode Island
Sage Investigational Site
Fort Worth, Texas
Sage Investigational Site
Houston, Texas
Sage Investigational Site
Richardson, Texas
Sage Investigational Site
Orem, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.